Functional interaction between pre-synaptic α6β2-containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum

British Journal of Pharmacology

Volumn 169, Issue 7, 2013, Pages 1600-1611

  Garcao P ^a,b   Szabo E C ^a,f   Wopereis, S ^c   Castro, A A ^a,c   Tome A R ^a,d   Prediger, R D ^c   Cunha, R A ^a,b   Agostinho, P ^a,b   Kofalvi A ^a,e  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

adenosine; adenosine A2A receptor; adenosine A2B receptor; dopamine; locomotor sensitization; nAChRs; nicotine; rat; striatum

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A2A RECEPTOR; ALPHA6BETA2 INTEGRIN; INTEGRIN; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA2A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; HABITUATION; LOCOMOTION; MALE; NERVE ENDING; NONHUMAN; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; SENSITIZATION; SYNAPTOSOME; WESTERN BLOTTING;

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; DOPAMINE; LOCOMOTOR SENSITIZATION; NACHRS; NICOTINE; RAT; STRIATUM;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CORPUS STRIATUM; DOPAMINE; GENE EXPRESSION REGULATION; MALE; MOTOR SKILLS; NICOTINE; PHENETHYLAMINES; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, NICOTINIC; SYNAPTOSOMES; TRIAZINES; TRIAZOLES;

EID: 84880322083     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12234     Document Type: Article

References (82)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. 1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem 101: 355-363.
3. Calabresi P, Di Filippo M, (2008). ACh/dopamine crosstalk in motor control and reward: a crucial role for alpha 6-containing nicotinic receptors? Neuron 60: 4-7.
4. 2A knockout mice. Neuropharmacology 51: 631-640.
5. Celik E, Uzbay IT, Karakas S, (2006). Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice. Prog Neuropsychopharmacol Biol Psychiatry 30: 50-55.
6. 2 and N-methyl-D-aspartate receptors regulate dopamine synthesis in rat striatal synaptosomes. J Neurochem 56: 1783-1788.
7. 2A receptor heteromers. J Neurosci 26: 2080-2087.
8. Cohen C, Welzl H, Bättig K, (1991). Effects of nicotine, caffeine, and their combination on locomotor activity in rats. Pharmacol Biochem Behav 40: 121-123.
9. Cools R, (2011). Dopaminergic control of the striatum for high-level cognition. Curr Opin Neurobiol 21: 402-407.
10. Cunha RA, Agostinho PM, (2010). Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis 20 (Suppl. 1): 95-116.
11. Cunha RA, Sebastião AM, (1993). Adenosine and adenine nucleotides are independently released from both the nerve terminals and the muscle fibres upon electrical stimulation of the innervated skeletal muscle of the frog. Eur J Physiol 424: 503-510.
12. 2A receptors in psychiatric disorders. Curr Pharm Des 14: 1512-1524.
13. Dagher A, Robbins TW, (2009). Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 61: 502-510.
14. 2A receptor induces protein kinase A-dependent functional modulation of human α3β4 nicotinic receptor. J Physiol 589: 2755-2766.
15. 2A receptors. Hippocampus 22: 276-291.
16. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, et al. (2008). In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron 60: 123-136.
17. Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, et al. (2010). Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci 30: 9877-9889.
18. 2A-receptors coupled to adenylate cyclase/cyclic AMP pathway downregulates nicotinic autoreceptor function at the rat myenteric nerve terminals. Neurochem Int 45: 641-651.
19. Exley R, McIntosh JM, Marks MJ, Maskos U, Cragg SJ, (2012). Striatal α5 nicotinic receptor subunit regulates dopamine transmission in dorsal striatum. J Neurosci 32: 2352-2356.
20. Ferré S, (2008). An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 105: 1067-1079.
21. 2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog Neurobiol 83: 332-347.
22. Ferreira SG, Lomaglio T, Avelino A, Cruz F, Oliveira CR, Cunha RA, et al. (2009). N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology 56: 676-683.
23. 2A adenosine receptor agonist on the ACh-induced increase in intracellular calcium of the glomus cells of the cat carotid body. Brain Res 1301: 20-33.
24. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE, (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133.
25. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM, (2005). Adenosine and brain function. Int Rev Neurobiol 63: 191-270.
26. Gerfen CR, Surmeier DJ, (2011). Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34: 441-466.
27. Girault JA, (2012). Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol 970: 407-429.
28. Gołembiowska K, Zylewska A, (1997). Adenosine receptors-the role in modulation of dopamine and glutamate release in the rat striatum. Pol J Pharmacol 49: 317-322.
29. 2A receptor-dependent manner. Brain Res 1113: 129-136.
30. 2A receptors. J Neurochem 108: 1208-1219.
31. Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, et al. (2010). Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 30: 5311-5325.
32. 3H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther 301: 651-660.
33. Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, et al. (2007). The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 74: 1235-1246.
34. Graybiel AM, (1991). Basal ganglia-input, neural activity, and relation to the cortex. Curr Opin Neurobiol 1: 644-651.
35. Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, et al. (2000). Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294: 1112-1119.
36. 2B adenosine receptors. Drug Des Discov 16: 217-226.
37. 3H]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol 58: 312-318.
38. Kayir H, Goktalay G, Yildirim M, Uzbay TI, (2009). Clozapine inhibits development and expression of nicotine-induced locomotor sensitization in rats. Synapse 63: 15-21.
39. Kempsill FE, Pratt JA, (2000). Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine. Br J Pharmacol 131: 997-1003.
40. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
41. 2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol 292: 426-431.
42. 3 receptor expression accompanying behavioural sensitization to nicotine in rats. Synapse 47: 176-183.
43. 2B receptor. J Pharmacol Exp Ther 320: 637-645.
44. Livingstone PD, Wonnacott S, (2009). Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 78: 744-755.
45. Lovinger DM, (2010). Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 58: 951-961.
46. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
47. Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M, (2002). Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80: 1071-1078.
48. 1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem 116: 273-280.
49. Meyer EL, Yoshikami D, McIntosh JM, (2008). The neuronal nicotinic acetylcholine receptors alpha 4* and alpha 6* differentially modulate dopamine release in mouse striatal slices. J Neurochem 105: 1761-1769.
50. Montandon G, Bairam A, Kinkead R, (2008). Neonatal caffeine induces sex-specific developmental plasticity of the hypoxic respiratory chemoreflex in adult rats. Am J Physiol Regul Integr Comp Physiol 295: 922-934.
51. Moriyama K, Sitkovsky MV, (2010). Adenosine A2A receptor is involved in cell surface expression of A2B receptor. J Biol Chem 285: 39271-39288.
52. Perez XA, Bordia T, McIntosh JM, Grady SR, Quik M, (2008). Long-term nicotine treatment differentially regulates striatal α6α4β 2* and α6(non-α4)β2* nAChR expression and function. Mol Pharmacol 74: 844-853.
53. Perry DC, Mao D, Gold AB, McIntosh JM, Pezzullo JC, Kellar KJ, (2007). Chronic nicotine differentially regulates α6- and β3-containing nicotinic cholinergic receptors in rat brain. J Pharmacol Exp Ther 322: 306-315.
54. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, et al. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177.
55. Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, et al. (1995). The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br J Pharmacol 115: 1096-1102.
56. 2A adenosine receptor antagonist, after enteric administration in rat, cat and dog. J Pharm Pharmacol 48: 601-606.
57. Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, et al. (2008). Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 23: 88-95.
58. Prediger RD, (2010). Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 20: S205-S220.
59. 2A receptors. Neurosci Lett 376: 160-165.
60. Prut L, Belzung C, (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviours: a review. Eur J Pharmacol 463: 3-33.
61. Quik M, Perez XA, Grady SR, (2011). Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders. Biochem Pharmacol 82: 873-882.
62. Raiteri L, Raiteri M, (2000). Synaptosomes still viable after 25 years of superfusion. Neurochem Res 25: 1265-1274.
63. 2A receptors in the hippocampus and striatum of the rat. Neuroscience 132: 893-903.
64. 2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 57: 121-134.
65. 2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem 92: 433-441.
66. A receptors. Proc Natl Acad Sci U S A 105: 15118-15123.
67. Ross GW, Petrovitch H, (2001). Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18: 797-806.
68. 2A receptors and basal ganglia physiology. Prog Neurobiol 83: 277-292.
69. Schoffelmeer A, De Vries T, Wardeh G, van de Ven H, Vanderschuren L, (2002). Psychostimulant-induced behavioural sensitization depends on nicotinic receptor activation. J Neurosci 22: 3269-3276.
70. Sebastião AM, Ribeiro JA, (2009). Tuning and fine-tuning of synapses with adenosine. Curr Neuropharmacol 7: 180-194.
71. Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, et al. (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol 80: 402-409.
72. Svikis DS, Berger N, Haug NA, Griffiths RR, (2005). Caffeine dependence in combination with a family history of alcoholism as a predictor of continued use of caffeine during pregnancy. Am J Psychiatry 162: 2344-2351.
73. Swanson JA, Lee JW, Hopp JW, (1994). Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Addict Behav 19: 229-256.
74. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. (2004). Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306: 1029-1032.
75. Threlfell S, Lalic T, Platt NJ, Jennings KA, Deisseroth K, Cragg SJ, (2012). Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75: 58-64.
76. Toyohara J, Hashimoto K, (2010). α7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med Chem J 4: 37-56.
77. Walsh RN, Cummins RA, (1976). The open-field test: a critical review. Psychol Bull 83: 482-504.
78. Wellman PJ, Clifford PS, Rodriguez J, Hughes S, Eitan S, Brunel L, et al. (2011). Pharmacologic antagonism of ghrelin receptors attenuates development of nicotine induced locomotor sensitization in rats. Regul Pept 172: 77-80.
79. Werling LL, Reed SC, Wade D, Izenwasser S, (2009). Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats. Int J Dev Neurosci 27: 263-269.
80. Whittaker VP, Michaelson IA, Kirkland RJ, (1964). The separation of synaptic vesicles from nerve-ending particles ('synaptosomes'). Biochem J 90: 293-303.
81. Wickens JR, Horvitz JC, Costa RM, Killcross S, (2007). Dopaminergic mechanisms in actions and habits. J Neurosci 27: 8181-8183.
82. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C, (2002). Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 22: 8785-8789. a Tecnologia Ciência e a Tecnologia a Tecnologia